A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

Lung Cancer

Volumn 54, Issue 1, 2006, Pages 69-77

  Ross, Helen J ^a   Hart, Lowell L ^b   Swanson, Paul M ^c   Rarick, Mark U ^d   Figlin, Robert A ^e   Jacobs, Andrew D ^f   McCune, David E ^g   Rosenberg, Arthur H ^h   Baron, Ari D ⁱ   Grove, Laurie E ^j   Thorn, Michael D ^k   Miller, Dennis M ^j,m   Drachman, Jonathan G ^j   Rudin, Charles M ^l,n  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b Florida Cancer Specialists   (United States)

^c Hematology Oncology Associates of Treasure Coast   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g MADIGAN ARMY MEDICAL CENTER   (United States)

^h GREENWICH HOSPITAL   (United States)

ⁱ Pacific Hematology Oncology Associates   (United States)

^j SEATTLE GENETICS INC   (United States)

^k Statistical Resources   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m ZYMOGENETICS INC   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Immunoconjugate; Lewis Y; Monoclonal antibody; Nsclc; Sgn 15; Targeted therapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; DOCETAXEL; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ANIMAL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MOUSE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOCONJUGATES; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 34249285842     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.020     Document Type: Article

References (25)

1. Cancer facts and figures. American Cancer Society; 2004.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31, 1.
3. Ginsberg RJ. Continuing controversies in staging NSCLC: an analysis of the revised 1997 staging system. Oncology (Williston Park) 1998;12:51-4.
4. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB nonsmall-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-10.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
6. Milton DT, Miller VA. Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer. Semin Oncol 2005;32:299-314.
7. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
8. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18: 2095-103.
9. Knost JA, Greco FA, Hande KR, Richardson RL, Fer MF, Oldham RK. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 1981;65:941-5.
10. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990;50: 2183-90.
11. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18:2282-92.
12. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R. Cell cycledependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996;49:832-41.
13. Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer 2001;93:590-600.
14. Trail PA, Willner D, Bianchi AB, et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res 1999;5:3632-8.
15. Hart L, Redfern C, Srinivas S, et al. A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with hormone refractory prostate carcinoma. Proc Am Soc Clin Oncol 2002 [Abstr 2433].
16. Hart LL, Nabell L, Saleh M, et al. A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel for the treatment of metastatic breast carcinoma. Proc Am Soc Clin Oncol 2003;22:174 [Abstr 696].
17. Nabell L, Sing A, Siegall C, Lobuglio A, Saleh M. A phase I study of combined modality therapy using SGN-15 with doc etaxel (Taxotere®) for the treatment of metastatic breast and colorectal carcinoma. Proc Am Soc Clin Oncol 2001 [Abstr 2251].
18. Nabell L, Saleh M, Marshall J, et al. Phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel for the treatment of metastatic breast and colorectal carcinoma. Proc Am Soc Clin Oncol 2002 [Abstr 55].
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
20. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
21. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822-31.
22. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer 1995;31A(Suppl 4):S1-6.
23. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the secondline treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
24. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.